Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
The New England Journal of Medicine|December 17, 2025
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 DiabetesStephen J Nicholls, Imre Pavo, Deepak L Bhatt, et al.
Cardiovascular Diabetology|November 26, 2020
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysisGilles R Dagenais, Lars Rydén, Lawrence A Leiter, et al.
The Journal of Clinical Endocrinology and Metabolism|April 21, 2022
Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND TrialTali Cukierman-Yaffe, Hertzel C Gerstein, Jan Basile, et al.
The Lancet. Neurology|June 21, 2020
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trialTali Cukierman-Yaffe, Hertzel C Gerstein, Helen M Colhoun, et al.
Lancet (London, England)|May 19, 2021
Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trialMichel Azizi, Kintur Sanghvi, Manish Saxena, et al.
The Lancet. Diabetes & Endocrinology|January 12, 2020
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trialHertzel C Gerstein, Robert Hart, Helen M Colhoun, et al.
Diabetes, Obesity & Metabolism|June 3, 2017
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutideHertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, et al.
Journal of the American Society of Nephrology : JASN|June 24, 2017
Effects of Intensive BP Control in CKDAlfred K Cheung, Mahboob Rahman, David M Reboussin, et al.
Lancet (London, England)|June 14, 2019
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trialHertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, et al.
Lancet (London, England)|June 14, 2019
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialHertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, et al.
Pageof 11